N@N

Market Maker Surveillance Report. CTC, RSH, KERX, MSLP, FURX, VTUS, Winning Stocks With Lowest Price Friction For Monday, Janu

January 28, 2013 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3940 companies with "abnormal" market making, 2696 companies with positive Friction Factors and 3035 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Canadian Tire Corp Ltd (NYSE:CTC), RadioShack Corp (NYSE:RSH), Keryx Biopharmaceuticals Inc (NASDAQ:KERX), MusclePharm Corp (OTC:MSLP), Furiex Pharmaceuticals Inc (NASDAQ:FURX), Ventrus Biosciences Inc (NASDAQ:VTUS). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  CTC     $0.540    0.18%     44,624       36.49%    36,318       29.70%    8,306        154     
  RSH     $0.580    0.22%     5,895,653    41.76%    4,846,494    34.33%    1,049,159    18,089  
  KERX    $2.730    0.80%     35,642,150   52.92%    30,972,204   45.99%    4,669,946    17,106  
  MSLP    $1.130    0.28%     43,292       18.04%    35,371       14.74%    7,921        70      
  FURX    $14.150   0.67%     719,327      52.90%    625,533      46.00%    93,794       66      
  VTUS    $0.500    0.23%     128,554      50.77%    124,631      49.23%    3,923        78      

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows CTC with a dollar gain Monday of $0.54000 and a Friction Factor of 154 shares. That means that it only took 154 more shares of buying than selling to move CTC higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

Canadian Tire Corp Ltd (NYSE:CTC) - IFM Investments Limited provides real estate services in the People s Republic of China. The company sells and leases residential properties in the secondary real estate market; and offers company-owned brokerage services, including property listing, advisory, and transaction negotiation and documentation services. It also provides mortgage management services, such as advisory services to home buyers and home owners in connection with the selection and procurement of mortgage products offered by commercial banks; and property financing, title transfers, and valuation services. In addition, the company offers franchise services, which primarily include the license to use or sub-franchise CENTURY 21 brand and system; training services; and the right to participate in marketing campaigns. Further, it provides agency services to residential real estate developers; planning, consulting, and brokerage services to commercial property developers; software development and licensing services; and fund management services. IFM Investments Limited was founded in 2000 and is headquartered in Beijing, China..

RadioShack Corp (NYSE:RSH) - RadioShack Corporation engages in the retail sale of consumer electronic goods and services through its RadioShack store chain. The company s mobility platform offers postpaid and prepaid wireless handsets, prepaid wireless airtime, tablet devices, and e-readers. Its signature platform provides home entertainment, wireless, computer, and music accessories; general purpose and special purpose power products; headphones; technical products; and services. The company s consumer electronics platform offers laptop computers, personal computing products, digital music players, residential telephones, global positioning system devices, cameras, digital televisions, and other consumer electronics products, as well as provides repair services. As of December 31, 2011, it operated 4,476 company-operated retail stores under the RadioShack brand name in the United States; 1,496 Target Mobile centers; 227 company-operated stores under the RadioShack brand, 9 dealers, and 1 distribution center in Mexico; a network of 1,091 RadioShack dealer outlets, including 33 located outside of North America; and 3 distribution centers in the United States. The company also sells products through its Website, radioshack.com. RadioShack Corporation was founded in 1899 and is headquartered in Fort Worth, Texas..

Keryx Biopharmaceuticals Inc (NASDAQ:KERX) - Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. Zerenex is in Phase III clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease on dialysis. The company has sublicense agreement with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York..

MusclePharm Corp (OTC:MSLP) - MusclePharm Corporation engages in the development, manufacture, and marketing of nutritional supplements for athletes. The company provides a line of nutritional supplements comprising of amino acids, herbs, and proteins to address various categories of an active lifestyle, including muscle building, weight loss, and fitness maintenance. Its products include Assault, a pre-performance amplifier that helps fight fatigue, boost performance, build muscle, increase intensity, and hydrate muscles; Battle Fuel, an herbal formula, which improves testosterone levels to drive strength, power, and lean muscle mass development; Bullet Proof that promotes sleep, optimizes anabolic/anti-catabolic environment, and stimulates growth hormone/testosterone output; Combat, which enables to receive protein, help in fat loss, support healthy body composition, nourish lean muscle, and speeds up recovery; and Re-con, a post-workout recharger that helps athletes recover, promote post workout growth and repair, and replenish vital nutrients. The company s products also comprise MuscleGel, which delivers proteins, carbohydrates, and vitamins; SHRED Matrix, a multi-level weight loss system; Armor-V, a multi-vitamin complex; BCAA, a branched chain amino acid complex; Creatine, the five blends of creatine that promotes strength, power, and endurance; ZMA Max, an anabolic mineral support formula; CLA Core, which supports energy sources for hard-training people on low-carb diets; Casein, a micellar casein protein; Hybrid N.O., a nitric oxide amplifier that promotes muscle pumps through enhanced vasodilation; Glutamine, a rapidly absorbed glutamine complex; PERFORM Elite, a pre-performance amplifier; and RECOVER Elite, a post-workout recharger. It sells its products through retail stores, distributors, and online stores in the United States, as well as through a network of distributors internationally. The company was founded in 2008 and is headquartered in Denver, Colorado..

Furiex Pharmaceuticals Inc (NASDAQ:FURX) - Furiex Pharmaceuticals, Inc., a drug development collaboration company, engages in the compound partnering business primarily in the United States. It collaborates with pharmaceutical and biotechnology companies to enhance the value of their drug candidates by applying its novel approach to drug development. The company has rights to compounds in various stages of development and commercialization, which include royalties, regulatory, and sales-based payments from Takeda Pharmaceuticals Company Limited for alogliptin and SYR-472 for the treatment of Type-2 diabetes, as well as for Liovel, a fixed dose combination tablet of alogliptin and pioglitazone HCL; from the collaboration with Alza Corporation for Priligy for the treatment of premature ejaculation; and licenses from Janssen Pharmaceutica, N.V., including MuDelta, a mu opioid receptor agonist and delta opioid receptor antagonist for the treatment of diarrhea-predominant irritable bowel syndrome, as well as for JNJ-Q for the treatment of acute bacterial skin and skin structure infections, and respiratory infections. The company was founded in 1998 and is headquartered in Morrisville, North Carolina. Furiex Pharmaceuticals, Inc. (NasdaqGM:FURX) operates independently of Pharmaceutical Product Development Inc. as of June 15, 2010..

Ventrus Biosciences Inc (NASDAQ:VTUS) - Ventrus Biosciences, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of late-stage prescription drugs for gastrointestinal disorders. It is developing three late-stage development product candidates, including Iferanserin ointment (VEN 309) for the topical treatment of symptomatic internal hemorrhoids; Diltiazem cream (VEN 307), a topical treatment for the relief of pain associated with anal fissures; and Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis, an FDA orphan indication. The company was formerly known as South Island Biosciences, Inc. and changed its name to Ventrus Biosciences, Inc. in April 2007. Ventrus BioSciences, Inc. was founded in 2005 and is headquartered in New York, New York..

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net